Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-03

Clinical Trial Update: A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 single-dose pharmacokinetic study of Lorcaserin hydrochloride in obese children aged 6 to 11 was completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belviq (lorcaserin)

Snippet

Sponsor: Eisai Inc. | Conditions: Obesity | Phase 1 | Status: COMPLETED